2
118 Journal of Natural Products, 2009, Vol. 72, No. 12
Extraction and Isolation. The fermented material (3 L) was freeze-
Guo et al.
14, 8.0 Hz, H-3a/3′a), 2.53 (2H, m, H-6b/6′b), 2.38 (2H, m, H-6a/6′a),
dried and extracted with ethyl methyl ketone (MEK; 3 × 500 mL),
and the organic solvent was evaporated to dryness under vacuum to
afford the crude extract (6.0 g). The extract was fractionated by silica
gel VLC using petroleum ether-EtOAc gradient elution. The fractions
eluted with 25 (80 mg), 30 (100 mg), 60 (100 mg), 70 (100 mg), and
2.30 (2H, m, H-7a/7′a), 2.15 (6H, s, H -10/10′).
3
Another sample of 3 (1.0 mg, 0.002 mmol), (R)-MTPA Cl (10.0
µL, 0.052 mmol), and pyridine-d (0.5 mL) were processed as described
above for 3a to afford 3b: H NMR (pyridine-d , 500 MHz) δ 6.46
(2H, s, H-8/8′), 4.74 (2H, d, J ) 8.0 Hz, H-9/9′), 3.29 (2H, d, J ) 14
Hz, H-3b/3′b), 2.86 (2H, t, J ) 8.0 Hz, H-4/4′), 2.70 (2H, m, H-7b/
7′b), 2.62 (2H, m, H-6b/6′b), 2.61 (2H, m, H-6a/6′a), 2.49 (2H, dd, J
5
1
5
9
5% EtOAc (30 mg) were individually separated by Sephadex LH-20
column chromatography (CC) using MeOH as eluent. The resulting
subfractions were combined into six fractions and subjected to further
purification by semipreparative RPHPLC (Agilent ZORBAX SB-C18
column; 5 µm; 9.4 × 250 mm; 2 mL/min) using different gradients to
) 14, 8.0 Hz, H-3a/3′a), 2.30 (2H, m, H-7a/7′a), 2.15 (6H, s, H
10′).
3
-10/
2
5
Epicoccin H (4): colorless powder; [R]
D
-175.0 (c 0.09, MeOH);
afford epicoccins E (1; 5.0 mg; 60% MeOH in H
2
O over 5 min,
UV (MeOH) λmax (log ε) 230 (3.83) nm; IR (neat) νmax 3416, 2922,
-
1 1 13
followed by 60-85% over 30 min), F (2; 5.0 mg; 60% MeOH in H
over 5 min, followed by 60-85% over 25 min), G (3; 7.0 mg; 35%
MeOH in H
2
O
1707, 1645, 1418,1246, 1076 cm ; H and C NMR data, see Table
2; HMBC data (DMSO-d , 600 MHz) H-3a/3′a f C-1/1′, 2/2′, 4/4′,
5/5′, 10/10′; H-3b/3′b f C-2/2′, 4/4′, 5/5′, 9/9′, 10/10′; H-4/4′ f C-2/
2′, 3/3′, 5/5′, 9/9′; H -6/6′ f C-5/5′, 7/7′, 8/8′; OH-7/7′ f C-6/6′, 7/7′,
8/8′; OH-8/8′ f C-7/7′, 9/9′; H-9/9′ f C-4/4′, 5/5′, 7/7′, 8/8′; H -10/
10′ f C-2/2′; key NOESY correlations (DMSO-d , 600 MHz) H-4/4′
T H-3a/3′a, 9/9′; H -10/10′ T H-3b/3′b; HRESIMS m/z 509.1023
(calcd for C20 Na, 509.1028).
Diphenylalazine A (5): white powder; [R]
MeOH); UV (MeOH) λmax (log ε) 215 (3.78), 295 (3.72) nm; IR (neat)
6
2
O over 5 min, followed by 35-85% over 25 min), and H
4; 5.0 mg; same gradient as in purification of 3); diphenylalazines A
5; 20 mg; 50% MeOH in water over 5 min, followed by 50-90%
O over 5 min,
followed by 60-100% over 30 min); and the known compounds
epicoccins A (7; 3.2 mg; 40% MeOH in H O over 5 min, followed by
0-80% over 30 min), B (8; 10 mg; same gradient as in purification
of 7), and D (9; 10 mg; same gradient as in purification of 6).
Epicoccin E (1): colorless needles (MeOH-H O); mp 273-275
+68.0 (c 0.17, MeOH); UV (MeOH) λmax (log ε) 224 (3.04)
nm; IR (neat) νmax 3438, 2923, 1727, 1666, 1422, 1323, 1287, 1133
(
(
2
3
over 30 min) and B (6; 2.0 mg; 60% MeOH in H
2
6
3
2
26 2 8 2
H N O S
2
5
4
D
+332.0 (c 0.48,
-1 1
2
νmax 3242, 2953, 2920, 1686, 1628, 1542, 1493, 1076 cm ; H and
13
2
5
°
C; [R]
D
6
C NMR data, see Table 3; HMBC data (DMSO-d , 400 MHz) H-1
f C-3, 5; H-6 f C-2, 5, 7, 8; H-7a f C-5, 6, 8, 9, 13; H-9 f C-7,
11, 13; H-10 f C-8, 12; H-11 f C-9, 13; H-12 f C-8, 10; H-13 f
C-7, 9, 11; H-14 f C-3, 5; H-7′ f C-2, 9′; H-9′ f C-11′; H-10′ f
C-8′, 12′; H-11′ f C-10′, 13′; H-12′ f C-8′, 10′; H-13′ f C-9′, 10′;
-
1
1
13
6
cm ; H and C NMR data, see Table 1; HMBC data (DMSO-d ,
6
8
00 MHz) H-3a f C-2, 4, 5, 9; H-4 f C-2, 4, 8, 9; H-6a f C-5, 7,
; H-7 f C-2, 5, 9; H-3′a f C-2′, 5′, 9′; H-4′ f C-2′, 3′, 5′; H-6′ f
C-2′, 5′, 7′, 8′; OH-8 f C-7, 8, 9; OH-7′ f C-7′; OH-8′ f C-8′, 9′;
HRESIMS m/z 461.0448 (calcd for C18 Na, 461.0453).
X-ray Crystallographic Analysis of 1. Upon crystallization from
MeOH-H O (10:1) using the vapor diffusion method, colorless crystals
NOESY correlations (DMSO-d
H-6 T H-9, 13, 14; H -7 T H-1, 9, 13; H-9 T H-1, 6; H-14 T H-6,
12′, 13′; H-7′ H-9′; HRESIMS m/z 329.1265 (calcd for
Na, 329.1266).
Absolute Configuration of Diphenylalazine A (5). A solution
6
, 400 MHz) H-1 T H-7a, 7b, 9, 13;
H
18
N O
2
7
S
2
2
2
5
T
2
19 18 2 2
C H N O
1
7
were obtained for 1, and a crystal (0.20 × 0.18 × 0.18 mm) was
separated from the sample and mounted on a glass fiber. Data were
collected using a Bruker SMART 1000 CCD diffractometer with
graphite-monochromated Mo KR radiation, λ ) 0.71073 Å at 173(2)
K. Crystal data: C18
P2
of 5 (1.5 mg) in 6 N HCl (1 mL) was heated at 100 °C for 16 h. Upon
removal of excess HCl under vacuum, the hydrolysate was placed in
a 1 mL reaction vial and treated with 1% solution of 1-fluoro-2,4-
dinitrophenyl-5-L-alanine amide (FDAA; 200 µL) in acetone followed
H
20
N
2
O
8
S
2
, M ) 456.48, space group monoclinic,
1
; unit cell dimensions a ) 10.861(2) Å, b ) 6.3257(13) Å, c )
3
by 1.0 M NaHCO (40 µL). The reaction mixture was heated at 45 °C
3
3
13.029(3) Å, V ) 887.9(3) Å , Z ) 2, Dcalcd ) 1.707 mg/m , µ )
0.356 mm , F(000) ) 476. The structure was solved by direct methods
for 1.5 h, cooled to room temperature, and then acidified with 2.0 N
HCl (20 µL). In a similar fashion, standard D- and L-Phe were
derivatized separately. The derivatives of the hydrolysate and standard
amino acids were subjected to RPHPLC analysis (Kromasil C18 column;
10 µm, 4.6 × 250 mm; 1.0-1.5 mL/min) at 25 °C using the following
-1
2
6
using SHELXL-97 and refined using full-matrix least-squares dif-
ference Fourier techniques. All non-hydrogen atoms were refined with
anisotropic displacement parameters, and all hydrogen atoms were
placed in idealized positions and refined as riding atoms with the relative
isotropic parameters. Absorption corrections were applied with the
3 3 4
gradient program: solvent A, 50 mM (Et NH) PO at pH 3.0; solvent
B, acetonitrile; linear gradient, 10%-35% B in 60 min with UV
detection at 340 nm. The retention times for the FDAA derivatives of
5 hydrolysate, standard L-Phe, and D-Phe were 44.75, 44.75, and 49.65
min, respectively.
27
Siemens Area Detector Absorption Program (SADABS). The 10 618
measurements yielded 3947 independent reflections after equivalent data
were averaged, and Lorentz and polarization corrections were applied.
The final refinement gave R
Epicoccin F (2): colorless powder; [R]
UV (MeOH) λmax (log ε) 215 (3.34) nm; IR (neat) νmax 3418, 2931,
2
5
1
) 0.0324 and wR
2
) 0.0814 [I > 2σ(I)].
Diphenylalazine B (6): white powder; [R]
D
+334.0 (c 0.213,
2
5
D
+52.0 (c 0.08, MeOH);
MeOH); UV (MeOH) λmax (log ε) 205 (4.04), 228 (3.84), 310 (3.93)
-
1
nm; IR (neat) νmax 3262, 2954, 2929, 1678, 1623, 1588, 1077 cm
;
-
1
1
13
1
13
2
1
5
856, 1664, 1417, 1320, 1051 cm ; H and C NMR data, see Table
; HMBC data (DMSO-d , 600 MHz) H-3a f C-2, 5, 9; H-3b f C-4,
, H-4 f C-2, 3, H-6a f C-5, 7, 8; H-9 f C-2, 4, 5, 7, 8; H-3′a f
H and C NMR data, see Table 3; HMBC data (DMSO-d
H-6 f C-2, 5; H -7 f C-5, 6, 8; H-10, 12 f C-8; H-7′ f C-2, 9′;
H-9′ f C-11′; H-10′, 12′ f C-8′; H -14 f C-3, 5; HRESIMS m/z
345.1210 (calcd for C19 Na, 345.1215).
6
, 400 MHz)
6
2
3
C-4′; H-3′b f C-2′, 5′; H-4′ f C-5′; H-6′a f C-5′, 7′, 9′; H-8′ f
C-2′, 7′, 9′; H-9′ f C-2′, 5′, 7′, 8′; OH-8 f C-9; OH-8′ f C-8′, 9′;
18 2 3
H N O
28
Anti-HIV Bioassays. Anti-HIV assays included cytotoxicity and
NOESY correlations (DMSO-d
m/z 479.0376 (calcd for C18
Epicoccin G (3): colorless powder; [R]
UV (MeOH) λmax (log ε) 224 (3.83) nm; IR (neat) νmax 3398, 2919,
6
, 600 MHz) H-9′ T OH-5′; HRESIMS
HIV-1 replication inhibition evaluations. Cytotoxicity was measured
4
H
20
N
2
O
6
S
3
Na, 479.0381).
by the MTT method as described in the literature. Cells (3 × 10 /well)
2
5
D
+69.0 (c 0.17, MeOH);
were seeded into a 96-well microtiter plate in the absence or presence
of various concentrations of test compounds in triplicate and incubated
-
1
1
13
2
851, 1699, 1651, 1543, 1405, 1193 cm ; H and C NMR data, see
Table 2; HMBC data (DMSO-d , 600 MHz) H-3a/3′a f C-1/1′, 2/2′,
/4′, 5/5′; H-6a/6′a f C-8/8′; H-6b/6′b f C-3/3′, 5/5′, 7/7′, 8/8′; H-7b/
′b f C-6/6′; H-9/9′ f C-4/4′, 7/7′, 8/8′; H -10/10′ f C-2/2′; NOESY
, 600 MHz) H-4/4′ T H-3a/3′a, 9/9′; H-6a/6′a
-10/10′ T H-3b/3′b; HRESIMS m/z 477.1125 (calcd for
Na, 477.1130).
Preparation of (R)-MTPA (3a) and (S)-MTPA Esters (3b). A
sample of 3 (1.0 mg, 0.002 mmol), (S)-MTPA Cl (10.0 µL, 0.052
mmol), and pyridine-d (0.5 mL) were allowed to react in an NMR
2
at 37 °C in a humid atmosphere of 5% CO . After a 4-day incubation,
6
cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) method. The concentration that
caused the reduction of viable cells by 50% (CC50) was determined. In
parallel with the MTT assay, a HIV-1 replication inhibition assay was
determined by p24 antigen capture ELISA. C8166 cells were exposed
to HIV-1 (MOI ) 0.058) at 37 °C for 1.5 h, washed with PBS to remove
4
7
3
correlations (DMSO-d
T H-8/8′; H
C H N O S
20 26 2 6 2
6
3
4
free viruses, and then seeded into a 96-well microtiter plate at 3 × 10
cells per well in the absence or presence of test compounds (indinavir
sulfate was used as positive control). After 4 days, the supernatant was
collected and inactivated by 0.5% Triton X-100. The supernatant was
diluted three times, added to the plate coating with anti-p24 McAb
(provided by Dr. Bin Yan, Wuhan Institute of Virology, Wuhan,
People’s Republic of China), and incubated at 37 °C for 1 h. After
washing five times with PBST, the HRP-labeled anti-p24 antibody
5
1
tube at ambient temperature for 6 days. The H NMR data of the
R-MTPA ester derivative (3a) were obtained directly on the reaction
1
mixture: H NMR (pyridine-d
(
(
5
, 500 MHz) δ 6.40 (2H, s, H-8/8′), 4.91
2H, d, J ) 8.0 Hz, H-9/9′), 3.33 (2H, d, J ) 18 Hz, H-3b/3b′), 3.07
2H, t, J ) 8.0 Hz, H-4/4′), 2.67 (2H, m, H-7b/7′b), 2.61 (2H, dd, J )